Correspondence 0001104659-25-009006 from Liminatus Pharma, Inc. (LIMN)
Liminatus Pharma, Inc.
Date: Feb. 4, 2025 · CIK: 0001971387 · Accession: 0001104659-25-009006
AI Filing Summary & Sentiment
File numbers found in text: 333-275409
Show Raw Text
CORRESP
1
filename1.htm
Iris Parent Holding
Corp.
6 Centerpointe
Drive #625,
La Palma, California
90623
VIA EDGAR
February 4, 2025
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tamika Sheppard and Tim Buchmiller
Re: Iris Parent
Holding Corp.
Acceleration Request for Post-Effective Amendment No. 3 to Registration Statement on
Form S-4
File No. 333-275409
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities
Act of 1933, as amended, Iris Parent Holding Corp. (the “Company”) hereby requests acceleration of the effective date
of the above referenced Registration Statement to 1:00 p.m., Eastern Time, on February 6, 2025, or as soon thereafter as practicable,
or at such other time as the Company or its outside counsel, Loeb & Loeb LLP, request by telephone that such Registration Statement
be declared effective.
Please contact Chauncey Lane of Holland &
Knight LLP at (214) 969-1278, or by email at Chauncey.Lane@hklaw.com, as soon as the Registration Statement has been declared effective,
or if you have any other questions or concerns regarding this matter.
[Signature Page Follows]
Sincerely,
/s/ Chris
Kim
Name: Chris Kim
Title: Chief Executive Officer
Signature Page to Acceleration Request
Letter